Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592972 | 0.83 | ALDH1A1 (0.37) | ALDH1A1HPGD | |
| SCHEMBL5049275 | 0.80 | GAA (0.37) | MAOAALDH1A1GAAHPGDFGFR1 | |
| SCHEMBL4607300 | 0.79 | MAOA (0.34) | MAOAALDH1A1GAAHPGDFGFR1 | |
| SCHEMBL4501360 | 0.78 | MAOA (0.35) | MAOAALDH1A1GAAHPGDFGFR1 | |
| SCHEMBL4605651 | 0.72 | ERBB2 (0.53) | — | |
| SCHEMBL4605656 | 0.72 | ERBB2 (0.53) | — | |
| SCHEMBL4605770 | 0.71 | ERBB2 (0.42) | FGFR1 | |
| SCHEMBL5050508 | 0.69 | DPP4 (0.39) | MAOAFGFR1 | |
| SCHEMBL4607023 | 0.67 | ESR1 (0.39) | — | |
| SCHEMBL6027103 | 0.67 | CYP19A1 (0.47) | GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761525-B1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| EP-1761525-A1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| US-7005526-B2 | Thioether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| WO-2005116019-A1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267179-A1 | NOVEL THIOETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267179-A1 | NOVEL THIOETHER DERIVATIVES | TPMT, TST, SULT1E1 | MAOA 4773/4885ALDH1A1 129/4885GAA 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.